The Diabetic Nephropathy Market is Growing Significantly with a CAGR of 6.0%

The global diabetic nephropathy market is anticipated to grow at a considerable CAGR of 5.3% during the forecast period (2021-2027). As per CDC, diabetes is the major reason for end-stage renal disease (ESRD). Around 26 million people in the US had diabetes in 2011, and amongst them, more than 200,000 people had end-stage renal disease due to diabetes. At this stage, a kidney transplant is the only treatment that can be implemented. However, medications, kidney dialysis, and acupuncture are other possible treatments. Medication is the primary treatment given to the patients. Diuretics, angiotensin-converting enzyme inhibitors, antioxidant inflammation modulator, angiotensin receptor blockers, renin inhibitors, calcium channel blockers, monocyte chemoattractant proteins inhibitor, and G protein-coupled receptors are the prominent medications given to patients of diabetic nephropathy.

Browse the full report description of "Global Diabetic Nephropathy Market Size, Share & Trends Analysis Report by Indication (Diabetes Type-1, and Diabetes Type-2), By Diagnosis (Urine Test, Imaging Test, Blood Test, Renal Function Test, and Renal Biopsy), and By Treatment (Medications, Kidney Dialysis, Kidney Transplant) Forecast Period 2021-2027" at https://www.omrglobal.com/industry-reports/diabetic-nephropathy-market

According to the International Journal of Advances in Medicine, around 79.4 million people will have diabetes in 2030, and by the time they get diagnosed they have been affected with some other nephropathy disease. This had given a clear vision of the growing diabetic nephropathy market in the future.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Indication

o By Diagnosis

o By Treatment

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape-  Abbott Laboratories, Bayer AG, AstraZeneca, Xortx Therapeutics Inc., Glaxosmithkline plc, Astellas Pharma, Inc., and AbbVie Inc., and others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Diabetic Nephropathy Market Report Segment

By Indication

• Diabetes Type-1
• Diabetes Type-2

By Diagnosis

• Urine Test
• Imaging Test
• Blood Test
• Renal Function Test
• Renal Biopsy 

By Treatment

• Medication
• Kidney Dialysis
• Kidney Transplant
• Acupuncture

Global Diabetic Nephropathy Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa

To learn more about this report request a free sample copy @  https://www.omrglobal.com/request-sample/diabetic-nephropathy-market